[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-progressive-cancer--5-years\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-progressive-cancer--5-years":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100545830","prospective-multicenter-cohort-study-to-validate-four-groups-of-biomarkers-for-assessing-lung-cancer-risk-among-patients-with-atheromatous-cardiovascular-disease-in-a-screening-pathway-100545830",false,"NCT06387017","Prospective Multicenter Cohort Study to Validate Four Groups of Biomarkers for Assessing Lung Cancer Risk Among Patients With Atheromatous Cardiovascular Disease in a Screening Pathway","BIOCEPTION","Inclusion Criteria:\n\n* 1- All PREVALUNG or PREVALUNG ETOILE participants\n* 2- Active or former smokers who have smoked daily for at least 10 years and have either atheromatous disease (coronary, lower limb, supra-aortic trunk, aortic, visceral or upper limb arteries) or a moderate or high coronary calcium score\\*, \\*\\*.\n\nInclusion criteria:\n\n* Age 45- 75 years and\n* Medical follow-up for smoking-related atheromatous pathology and\n* daily smoking for at least 10 years prior to disease (for smoking, there are no quantitative criteria or withdrawal times)\n\n  * visual coronary calcium score quantified by a radiologist on a chest CT scan.\n\n    3- Individuals at risk of lung cancer without atheromatous disease or moderate or high calcium score being managed for a tobacco-related disease (chronic bronchitis or non-progressive cancer \\> 5 years) or with eligibility criteria for lung cancer screening (inclusion criteria in the NLST or NELSON studies or American recommendations)\\*\\*.\n\nInclusion criteria :\n\n* Age 45- 75 and\n* Medical follow-up for a smoking-related pathology:\n* chronic obstructive pulmonary disease \u002F emphysema, or\n* history of non-progressive cancer \\> 5 years, including ENT, lung, breast, cervix, excreto-urinary tract, bladder, esophagus, stomach, pancreas, liver, kidney, chronic myeloid leukemia.\n\nand\n\n\\- daily smoking for at least 10 years prior to the disease (for smoking, there are no quantitative criteria or withdrawal periods).\n\nOr\n\nInclusion criteria in NLST :\n\n* Age 55 - 74\n* Cumulative smoking ≥ 30 pack-years\n* active or weaned for less than 15 years Or\n\nNELSON inclusion criteria :\n\n* Age 50-75\n* Smoking :\n* \\> 15 cigarettes \u002FD for more than 25 years or\n* \\> 10 cigarettes \u002FD for more than 30 years\n* active smoking or cessation \\\u003C 10 years Or\n\nAmerican recommendations :\n\n* Age 50 - 80\n* Smoking ≥20 PA\n\nExclusion Criteria:\n\n* cancer history \\\u003C 5 years (except carcinoma in situ of the uterine cervix, basal cell carcinoma of the skin, non-invasive urothelial carcinoma treated for curative purposes without CT lung surveillance, prostate cancer with unmeasurable PSA)\n* symptoms of lung cancer (involuntary weight loss \\> 7 kg in 1 year, hemoptysis)\n* known history of pulmonary nodule requiring specialized follow-up\n* history of pulmonary fibrosis or pulmonary hypertension\n* active pulmonary parenchymal infection\n* severe cardiac or respiratory insufficiency (rest dyspnea)\n* performance status (WHO) 2, 3 or 4\n* patient not affiliated to the social security system (beneficiary or beneficiary's beneficiary)\n* patient deprived of liberty\n* patients under guardianship or trusteeship\n* pregnant or breast-feeding women","ALL","45 Years","80 Years",{"count":20,"type":21},750,"ESTIMATED","INTERVENTIONAL",[24],"NA","Interventional study with minimal risks and constraints, with evaluation of the incidence of lung cancers by low-dose thoracic CT scan without injection of contrast medium, of the immunological, inflammatory and metabolic blood profile and of the microbiota; systematic proposal of smoking cessation for active smokers or assistance in maintaining cessation.",[27,28,29,30],"Smoking-related Pathology","Atheroma","Non-progressive Cancer > 5 Years","Lung Cancer","RECRUITING","2024-04-24",{"date":34,"type":35},"2024-04-26","ACTUAL",{"date":37,"type":35},"2024-04-02",{"date":39,"type":21},"2029-07",{"name":41,"class":42},"Assistance Publique Hopitaux De Marseille","OTHER"]